Castle Biosciences, Inc. Chief Commercial Officer W. Tobin Juvenal filed a Form 4 on October 28, 2026, reporting the sale of 3,288 shares of common stock on October 26, 2026, under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: W. Tobin Juvenal, Chief Commercial Officer of Castle Biosciences, Inc. (NASDAQ:CSTL)
  • Shares disposed: 3,288 shares of common stock sold on October 26, 2026
  • Weighted-average price: $33.08 per share, with individual trade prices ranging from $32.63 to $33.46, inclusive
  • Remaining ownership: 45,431 shares of common stock held directly following the transaction
  • 10b5-1 plan: The sale was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 28, 2026
  • Transaction code: S (sale), executed in multiple trades

Juvenal's October 2026 Share Sale Under 10b5-1 Plan

According to the filing, W. Tobin Juvenal, who serves as Chief Commercial Officer of Castle Biosciences, Inc., disposed of 3,288 shares of the company's common stock on October 26, 2026. The transaction was coded "S," indicating a sale, and was carried out directly. The filing identifies the issuer as Castle Biosciences Inc, listed on NASDAQ:CSTL.

The filing discloses that the sale was executed in multiple trades at prices ranging from $32.63 to $33.46, inclusive, with the reported figure of $33.08 reflecting the weighted-average sale price. The reporting person has undertaken, according to the filing, "to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."

The filing further states that the transaction was made pursuant to a Rule 10b5-1 plan that Juvenal adopted on May 28, 2026. Following the reported sale, Juvenal's direct beneficial ownership in Castle Biosciences common stock stands at 45,431 shares, according to the filing. The Form 4 was signed by Frank Stokes as attorney-in-fact on October 28, 2026.

What Was Disclosed

The filing reports that Castle Biosciences Chief Commercial Officer W. Tobin Juvenal sold 3,288 shares of common stock on October 26, 2026, at a weighted-average price of $33.08, under a Rule 10b5-1 plan adopted May 28, 2026, retaining 45,431 shares directly.